| abstract |
The present disclosure provides for the use of the HSP90 inhibitor MPC-0767 as monotherapy and in combination with additional active agents including, but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoints inhibitors, DNMT inhibitors, ATO, and chemotherapeutic agents) for the treatment of cancers, including but not limited to hematopoietic cancers and lung cancers. The present disclosure also provides related compositions and methods of use. |